Furazabol is an oral anabolic steroid derived from dihydrotestosterone. This agent is moderately anabolic, with only mild androgenic properties. This is no doubt due to the modification of the steroid’s A-ring, which allows the steroid structure to remain stable and bind receptors in muscle tissue long enough to provide an anabolic benefit. Dihydrotestosterone, in comparison, is a poor anabolic, quickly metabolized in muscle tissue to inactive metabolites. The gains associated with furazabol are not extreme, and would more closely resemble the quality growth of a mild non-aromatizing anabolic like stanozolol or drostanolone, instead of the watery bulk of a testosterone. For this reason, furazabol is most often applied during cutting phases of training, and by athletes in speed and weight-restricted sports.
|Brand name||Miotolan, Furazabol|
|Progestational Activity||no data available (low)|
Furazabol was first described in 1965. The only modern pharmaceutical preparation of record containing furazabol, at least known to researchers in the West, was Miotolan from Daiichi Seiyaku Labs in Japan, which was sold in Japan mainly during the 1970’s and ’80’s. The agent itself is scarcely mentioned in the Western medical literature, and consequently a great deal of myth has come to surround it among athletes. A realistic appraisal sits this agent in a very similar class to stanozolol, however, with both agents being moderately strong anabolics with low androgenic activity. Aside from this, it is difficult to ascribe any drastically unique traits to this drug.
Furazabol was a popular steroid among Olympic athletes during the 1980’s, when it was quietly known among certain trainers that testing officials had not yet identified the agent, and therefore could not test for it. Dr. Jamie Astaphan, the physician that accompanied Ben Johnson to the 1988 Olympics in Seoul, reportedly was giving Johnson (and numerous other athletes at the time) furazabol, knowing the drug would not be detectable. It remains uncertain how Johnson ultimately tested positive for stanozolol, which Dr. Astaphan strongly denied giving his athletes. Within two years, methods for the detection of furazabol in urine were published, immediately eliminating any value this agent formerly possessed as a steroid undetectable to drug screeners.
Today, furazabol is very scarcely known to bodybuilders. The Miotolan brand from Japan was discontinued many years ago, and no pharmaceutical preparation containing furazabol has been known to exist since. The drug is occasionally located on the black market, however, due to the fact that is it still produced in bulk (as a raw material for product manufacturing) in Asia. From there it is obtained by underground steroid manufacturing operations in the West, and produced into oral tablets and capsules. Currently the actual number of products containing furazabol is small, although could easily be expanded if market demand for the agent increases. It remains unlikely that an actual prescription product containing this steroid will ever be seen again.
How is Furazabol Supplied
Furazabol is no longer available as a prescription drug preparation. When sold it came in the form of tablets containing 1mg of steroid.
Structural Characteristics of Furazabol
Furazabol is a modified form of dihydrotestosterone. It differs by: 1) the addition of a methyl group at carbon 17-alpha, which helps protect the hormone during oral administration, and 2) the attachment of a furazan group to the A-ring, replacing the normal 3-keto group. When viewed in the light of 17-alpha methyldihydrotestosterone, the A-ring modification on furazabol seems to considerably increase its anabolic strength while reducing its relative androgenicity.
Furazabol Side Effects (Estrogenic)
Furazabol is not aromatized by the body, and is not measurably estrogenic. An anti-estrogen is not necessary when using this steroid, as gynecomastia should not be a concern even among sensitive individuals. Since estrogen is the usual culprit with water retention, this steroid instead produces a lean, quality look to the physique with no fear of excess subcutaneous fluid retention. This makes it a favorable steroid to use during cutting cycles, when water and fat retention are major concerns.
Furazabol Side Effects (Androgenic)
Although classified as an anabolic steroid, androgenic side effects are still possible with this substance, especially with higher doses. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Women are warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. Furazabol is a steroid with relatively low androgenic activity relative to its tissue-building actions, making the threshold for strong androgenic side effects comparably higher than with more androgenic agents such as testosterone, methandrostenolone, or fluoxymesterone. Note that furazabol is unaffected by the 5-alpha reductase enzyme, so its relative androgenicity is not affected by the concurrent use of finasteride or dutasteride.
Furazabol Side Effects (Hepatotoxicity)
Furazabol is a c17-alpha alkylated compound. This alteration protects the drug from deactivation by the liver, allowing a very high percentage of the drug entry into the bloodstream following oral administration. C17-alpha alkylated anabolic/androgenic steroids can be hepatotoxic. Prolonged or high exposure may result in liver damage. In rare instances life-threatening dysfunction may develop. It is advisable to visit a physician periodically during each cycle to monitor liver function and overall health. Intake of c17-alpha alkylated steroids is commonly limited to 6-8 weeks, in an effort to avoid escalating liver strain.
Furazabol Side Effects (Cardiovascular)
Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Furazabol has a strong effect on the hepatic management of cholesterol due to its non-aromatizable nature, structural resistance to liver breakdown, and route of administration. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.
Note that furazabol is often mistakenly described as a steroid with unique beneficial cholesterol-lowering effects. Such statements usually make reference of studies conducted in the early 1970’s, which examined the lipid-lowering effects of the agent. Such a position, however, lacks a modern perspective of the drug. To draw a parallel, during the early 1970’s there was research done on oxandrolone, demonstrating a lipid-lowering effect. Upon closer inspection, however, it was shown that oxandrolone tends to lower HDL (good) cholesterol, increasing the HDL-LDL ratio and atherogenic risk. General cholesterollowering applications for the drug never materialized. The same is true for furazabol. Some have gone so far as to recommend this steroid to those with high cholesterol! Such use absolutely should be avoided.
To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.
Furazabol Side Effects (Testosterone Suppression)
All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse,necessitating medical intervention.
Furazabol Administration (Men)
An effective dosage of furazabol seems to begin in the range of 10-20 mg daily for men, taken for no longer than 6 or 8 weeks. At this level it seems to impart a measurable musclebuilding effect, which is usually accompanied by fat loss and increased definition. Doses of 30 mg per day or more considerably increase the anabolic potential of the drug, but at the expense of greater hepatotoxicity. The muscle-building activity of furazabol could, instead, be further enhanced by the addition of an injectable anabolic such as Deca-Durabolin or Equipoise. In this case, the combination should provide a noteworthy gain of solid, quality muscle mass without a loss of definition due to water retention. We could alternately use a more potent aromatizable androgen such as testosterone, although here the gains may be accompanies by some level of water retention, and potentially a decrease in muscle definition.
Furazabol Administration (Women)
In the athletic arena, an effective oral daily dosage would fall in the range of 2-5 mg, taken in cycles lasting no more than 4-6 weeks to minimize the chance for virilization. As with all steroids, virilizing side effects are still possible in women, but remain rare with conservative dosing.
Furazabol is no longer produced as a prescription drug product, although underground preparations containing this steroid may be located.
Anabolic Steroid Guide reference
Furazobol, known by its trade name, Miotolan, is a synthetic derivative of dihydrotestosterone. Until 1990 this steroid was not detectable during any doping tests and could thus be taken by athletes even on the day of a competition. When looking at the application of Miotolan you learn even more unusual things: This steroid is used as a lipid reducer. It is suitable for long-term treatment of arteriosclerosis and hypercholesterolemia. Miotolan reduces the cholesterol level and increases the "good" HDL value. In Japan Miotolan is a standard treatment to lower cholesterol levels.
This steroid does not cause water and salt retention and does not aromatize. Since the tablets are effective for only a brief period of time they must be taken several times a day. Miotolan has a predominantly androgenic effect and only a very low repression of the body's own testosterone production. Although it is potentially hepatoxic a possible reduced liver function seems unlikely if the daily manufacturer recommended dose of 2-6 mg is not exceeded. Since athletes use considerably higher dosages the risk of liver poisoning cannot be excluded. The usual question-What is a performance improving dosage?-is difficult to answer. It is difficult because we do not know anybody who has ever taken this compound and because technical literature does not have anything to report in this regard either. The daily dosage should be at least 10-20 tablets, that is 10- 20 mg/day. Due to its low substance amount per tablet and its high cost, this steroid will probably not be successful with body-builders. (Possible doubts by readers that this steroid perhaps does not exist are inappropriate.) However, this steroid really does exist.
Wlliam Llewellyn (2011) - Anabolics
Anabolic Steroid Guide